B-cell therapy for multiple sclerosis (MS) was first approved in 2017, after the anti-CD20 agent ocrelizumab (Ocrevus) ...

Updates in relapsing-remitting MS from AAN 2025 examine neurofilament light protein level as a prognostic biomarker, safety and efficacy of ofatumumab, and benefit of early initiation of ozanimod.

Ofatumumab was first approved by the FDA as a cancer drug in chronic lymphocytic leukaemia (CLL), under the brand name Arzerra, in 2014 when it was owned by GlaxoSmithKline.

Novartis’ cancer therapy ofatumumab has moved closer to its second life as a treatment for multiple sclerosis, with a regulatory decision in the US due in June and in Europe in the first half of ...

However, as most data is registry-based and previous trials did not directly compare aHSCT with the most efficacious DMTs, Alemtuzumab, Ocrelizumab, Cladribine and Ofatumumab, questions remain over ...